







































Volume 03 Issue 05-2023 24 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

 

 

 

 

 

ABSTRACT 

Limitations in trial design, accrual, and data reporting impact efficient and reliable drug evaluation in cancer clinical 

trials. These concerns have been recognized in neuro-oncology but have not been comprehensively evaluated. We 

conducted a semi- automated survey of adult interventional neuro-oncology trials, examining design, interventions, 

outcomes, and data availability trends. Trials were selected programmatically from ClinicalTrials.gov using primary 

malignant CNS tumour classification terms. Regression analyses assessed design and accrual trends; effect size 

analysis utilized survival rates among trials investigating survival. 

KEYWORDS 

Primary Central Nervous System malignancies; clinical trial design trends; trial accrual; treatment effect size 

assumptions; leveraging of trial registry data. Interdisciplinary; Iran; NOSC; brain tumours; neuro-oncology. 

  Research Article 

 

AWARENESS AMONG PEOPLE BASED ON NEURO ONCOLOGY 
 

Submission Date: May 09, 2023, Accepted Date:  May 14, 2023,  

Published Date: May 19, 2023  

Crossref doi: https://doi.org/10.37547/ajbspi/Volume03Issue05-04 

 

 

Mirkhamidova Sevara Mirmakhmudovna 
Assistant Of The Department Of The Public Health And Management, Tashkent Medical Academy, Uzbekistan 

 

Muyassarova Mukhabbat Mukhammadiyevna 
Senior Teacher Of The Department Of Public Health And Management, Tashkent Medical Academy, Uzbekistan 

 

Abdurashitova Sharafat Abdumajidovna 
Senior Teacher Of The Department Of Public Health And Management, Tashkent Medical Academy, Uzbekistan 

 

Karimbayev Shakhrambay Dexkanbayevich 
Associate Professor (Phd) Of The Department Of Public Health And Management, Tashkent Medical Academy, 

Uzbekistan 

 

Tanisha Rahim 
Student Foreign Faculty Tashkent Medical Academy, Uzbekistan 

 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://doi.org/10.37547/ajbspi/Volume03Issue05-04
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 03 Issue 05-2023 25 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

INTRODUCTION 

Despite important advances in the molecular 

understanding of malignant primary CNS tumours and 

efforts to translate these advances into clinical benefit, 

there has been limited progress in treatments across 

neuro-oncology. Therapeutic drug development in 

neuro- oncology is complicated by a unique set of 

challenges including vast inter- and intra-tumoral 

heterogeneity, complex interactions of the tumour 

with the neuronal and tumour microenvironments, the 

existence of the blood-brain/tumour barrier which 

limits the penetrability of compounds, a distinct and 

isolated immunologic locale, and the inability of 

preclinical models to recapitulate this complexity. 

Beyond scientific challenges, past studies have pointed 

to shortcomings in clinical trial design (including a lack 

of randomization, absence of controls, overly 

restrictive eligibility criteria, and low accrual) as 

contributing to the translation failure of potentially 

promising therapies. 

discussions have highlighted the need to address 

design challenges through novel trial designs that the 

scope of our survey included past, ongoing, and 

planned trials assessing interventions on any malignant 

CNS tumour diagnoses; we evaluated trial design 

characteristics, estimated treatment effect size 

assumptions implied by the trial designs, overviewed 

the extent of data availability, and summarized 

reported efficacy and toxicity of interventions. 

Research and practice of neuro-oncology compiles 

clinical neuroscience expertise from neurosurgery, 

radiation oncology, neuroradiology, medical oncology, 

neuropathology and related disciplines to optimize 

planning and therapy in central nervous system 

malignancies. Such an interdisciplinary context 

prompted health-care providers from all related 

disciplines to establish the Neuro-Oncology Scientific 

Club (NOSC) in Iran and let it flourish since 3 years ago. 

With the advent of advanced technologies and 

through continued share of experience, NOSC 

members have tried to provide more integrated 

diagnoses and therapeutic care to brain tumour 

patients across the country. NOSC activities revolve 

around some key tenets including dissemination of 

education and updates, facilitation of institutional 

collaborations; data registry and patients' awareness. 

By virtue of recent insights on molecular 

characterization of brain tumours such as codeletion of 

chromosomes 1p and 19q in anaplastic gliomas and O6-

methylguanine-DNA methyltransferase (MGMT) 

promoter methylation in glioblastoma, a range of 

translational research is being followed within NOSC. 

The most recent NOSC meeting which was held in 

Tehran, recapitulated main advances and dealt with 

the current debates on functional neurosurgery, 

biological markers and neuroimaging, risk prediction 

models in high grade gliomas and clinical issues in 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 26 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

paediatric neuro-oncology. This article gives an 

overview of current hotspots in neuro-oncology 

research and practice which are pursued within NOSC 

[1]. 

Survivorship has become a significant topic within 

oncologic care. The tools and means by which the 

provision of survivorship care can be implemented and 

delivered are in development and are the focus of 

significant research oncology-wide. These tools and 

methods include innovations of survivorship care 

delivery, survivorship care plans, and improving 

communication among all stakeholders in an individual 

patient's care as the means to elevate health-related 

quality of life. The merits of these survivorship care 

provisions in the field of neuro-oncology and its 

patients' exigent need for more patient-centric care 

focused on living with their illness are discussed. Brain 

metastases occur commonly in patients with advanced 

solid malignancies. Yet, less is known about brain 

metastases than cancer-related entities of similar 

incidence. Advances in oncologic care have heightened 

the importance of intracranial management. Here, in 

this consensus review supported by the Society for 

Neuro-Oncology (SNO), we review the landscape of 

brain metastases with particular attention to 

management approaches and ongoing efforts with 

potential to shape future paradigms of care [2]. 

Adolescents and young adults (AYA) comprise a 

specific group of oncology patients with a distinct 

biological and epidemiological spectrum of central 

nervous system neoplasms. It has been well 

documented that they differ clinically, especially in 

relation to prognosis and chemotherapy tolerance; 

however, the underlying reasons for this are unclear. 

Recent advances in the genomics of both childhood 

and adult brain tumors have provided new 

explanations and insights into the previously described 

age-dependent heterogeneity. Herein, we summarize 

the current state of the AYA population in neuro-

oncology, specifically how biological advances can help 

personalize therapy for this unique group of patients. 

The management of brain tumors developed in 

adolescents and young adults (AYAs) is challenging 

because of their histological heterogeneity and low 

incidence. The brain tumor and its treatment 

interventions can negatively affect neurological, 

neurocognitive, and endocrinological function, and 

dramatically affect the circumstances of AYA patients 

progressing to further education, employment, and 

marriage. Specific support is thus necessary to 

maintain the quality of life (QOL) of AYA brain tumor 

patients. AYA patients and survivors require active 

intervention and support for returning to school or 

work, progressing to further education, finding 

employment, and preserving fertility. Recent cancer 

genome profiling revealed that AYA gliomas include 

pediatric- and adult-type genetic alteration. Insights 

into the biology underlying the distribution of tumors 

in AYAs may influence the development of prospective 

trials. A more individualized view of brain tumors may 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 27 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

influence stratification of patients' in future clinical 

studies as well as selection for molecular targeted 

therapy.[3] 

Selection and measurement of appropriate outcomes 

in clinical trials is critical. A trial or study outcome is a 

measurable variable examined in response to a 

treatment or intervention, to assess effectiveness or 

harm. Traditional measures of response or time-

dependent metrics are important (Eg., radiological 

tumor response or survival), but are somewhat limited 

because they fail to characterize the functional or 

symptomatic effect of the tumor on the person. 

Outcomes should measure, either directly or indirectly, 

how patients feel, function, and survive. Patients want 

to live longer, but not necessarily at the expense of 

quality of life. 

The US Food & Drug Administration (FDA) describe 

four categories of clinical outcome assessment (COA): 

patient-reported (eg, health-related quality of life by 

questionnaire), clinician-reported (eg, performance 

status), observer-reported (eg, informal caregivers), or 

performance outcomes (eg, neurocognitive 

tests).Brain tumor clinical trials increasingly include the 

measurement of patient-reported outcomes, but the 

level of reporting may be suboptimal. 

COS should only be developed for neuro-oncology if 

there is a clearly identified need and future uptake is 

anticipated. Examples of need include standardizing 

outcomes to allow meta-analysis and generation of 

new knowledge, or identifying outcomes of core 

importance to patients that are not currently 

measured in clinical trials—a scenario which may result 

in treatment recommendations that are not 

acceptable to patients. COS are increasingly being 

developed for routine practice which may also justify 

need. Future uptake requires broad engagement of 

healthcare professionals conducting neuro-oncology 

research. The COS should be widely disseminated 

through conference presentations, publications, and 

communication with policy makers, charities, and 

patient organizations [4]. 

The Core Outcome Measures in Effectiveness Trials 

(COMET) initiative brings together people interested in 

the development and application of COS. New COS 

projects should be registered, and if the same COS are 

listed as under development by another research 

group or if overlap exists, COMET facilitates 

communication between research groups to promote 

collaboration and prevent duplication of effort and 

research waste [6]. 

The existence of a COS with similar scope to one 

planned does not constitute an absolute 

contraindication to its development, and may be 

beneficial within neuro-oncology. Consider the 

hypothetical situation of a disease-specific COS being 

developed for pediatric medulloblastoma, and a 

researcher developing a broader COS defining 

outcome measures for clinical trials of surgically 

managed posterior fossa tumors. The disease-specific 

COS may include outcomes highly relevant to 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 28 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

medulloblastoma key stakeholders, eg, disease-

specific treatments such as adjuvant 

chemoradiotherapy. However, a broader COS that 

reflects surgical intervention for a particular 

anatomical location (ie, posterior fossa), will identify 

adverse events associated with surgery that will be 

relevant to other key stakeholders, including those 

invested in medulloblastoma. The combination of a 

disease-specific and treatment-specific COS will cover 

outcomes of relevance to all key stakeholders [7]. 

CNS tumors are the most common solid tumor in those 

aged 0–19 years, represent 6% across all ages, and are 

the most common cause of cancer death in this 

population. Pediatric brain tumors are associated with 

high morbidity which may have lifelong consequences 

for survivors, both from the disease and treatment. 

Classifying and reporting postoperative morbidity in 

pediatric brain tumors is challenging. The disease area 

is highly heterogeneous, anatomically distributed, and 

associated with location-specific morbidity. Pathology 

may also dictate the aggressiveness of surgical intent 

and the level of postoperative morbidity which is 

acceptable to achieve adequate disease control. In 

addition, presurgical neurological condition and co-

morbidity status can be variable at diagnosis and may 

contribute to cumulative postoperative morbidity. 

Finally, many children will go on to have systemic 

therapies or radiotherapy which also affect tumor-

associated morbidity. Transparent and reproducible 

morbidity reporting helps to manage patient and 

parent expectations, provides a standardized way to 

compare adverse events in clinical or research studies 

and provides a benchmark to compare clinical services. 

The application of existing morbidity tools to report 

pediatric brain tumor surgery harms is inadequate. The 

COMBAT project will develop a core set of adverse 

outcomes for children undergoing tumor biopsy and/or 

resection which are determined to be of importance to 

all key stakeholders [5]. 

Neuro-oncology and palliative care: a challenging 

interface Palliative care is defined by the World Health 

Organization as “an approach that improves the 

quality of life of patients and their families facing the 

problems associated with life-threatening illness, 

through the prevention and relief of suffering by 

means of early identification and impeccable 

assessment and treatment of pain and other problems, 

physical, psychosocial and spiritual.” Palliative care 

encompasses symptom control and provision of 

practical support to patients and their carers—from 

first referral through terminal care and death and into 

bereavement.  

The goal of palliative care is to maximize quality of life, 

drawing on the skills of a multidisciplinary team to help 

the patient live as actively as possible whilst neither 

hastening nor postponing death.  Palliative care can 

play an important role in the management of 

malignant and nonmalignant conditions, in both 

inpatient and outpatient settings [6]. 

MATERIALS AND METHODS  

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 29 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

This study used an online google forms questionnaire 

as the instruments. Invitation to people in this survey 

was sent through via email and among social media 

platforms. It was sent this way because everyone 

nowadays are on social media platforms it would be 

easy to spread awareness in this way. Therefore, using 

Google form to reach each participant is the best 

choice. 

 The target respondents are the young people of 

Tashkent, Uzbekistan and India under the age of 25 

because the young people ratio are more in this area 

and they need a good awareness among them . The 

questions in the developed questionnaire were 

distributed for this pilot to test the awareness of public 

on neuro-oncology. The population of this survey was 

102 members. This work is done to create awareness 

among people on neuro oncology. The search for 

literary sources was carried out using the bibliographic 

databases Web of Science, Scopus, DBLP, PubMed. 

When selecting sources, they paid attention to 

experimental articles, literary reviews, the number of 

their citations over the past year. 

RESULTS 

The survey were conducted using information and 

communication technologies, booklets, brochures, 

presentations, etc. All were asked to answer using a 

specially designed public awareness on neuro-

oncology questionnaire. The table below show the 

results of the survey. People of about 102 were under 

survey. Among them, Male (40.8%), Female (59.2%) and 

Others (0%) 

 

MALE
59%

FEMALE
41%

GENDER

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 30 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

The age of the participants was from 18-25 years old (78.4%), from 26-40years old (13.7%), from 41-60 years old (7.8%) 

and from 60 and above (0%). The respondents are mostly under 25 because my survey reached to most of the young 

people whom I’m in contact with. Even-though , I also received response from middle-aged people through my family 

members and relations in India . 

 

Most of the participants of the survey responded the correct answer ‘No’(78%). 

So the result tells that the disease is not contagious by the people. Even-though, some people are not aware that it is 

not infectious and answered as ‘Yes’ (11%) 

 

 

 

 

 

 

 

 

 

 

 

Under 18
20%

from 25-30
78%

above 45
2%

AGE

yes
11%

no
78%

Don’t know
11%

Do you think its infectious or non infectious?

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 31 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

So more than half (55%) of the people in my survey are suffering from any kind of brain related diseases. So this 

portrays that these diseases are becoming familiar in our life cycle nowadays. 

 

Nowadays Headache (37%) became an usual symptom among teenagers and adults because of lots of stress they go 

through in this era. Due to this the cycle continues as Weakness (35%) ,Change in personality (12%) ,Nausea (9%) and 

goes on. 

 

Most of the people doesn’t know about Neuro-oncology and they are not aware about this disease. 

yes
55%

no
36%

maybe
9%

Are you suffering from any brain diseases or any type of 
tumours or brain cancer?

weakness
35%

seizures
2%

Difficulty in walking
5%

changes in 
personality

12%

Nausea
9%

Headaches
37%

Are you going through any of these symptoms?

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 32 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

 

 

 

 

It’s not a prevalent disease in this era because people never share that they have any oncology disease (69%). 

 

Yes
30%

No
69%

Maybe
1%

Have you seen people suffering from this around you?

yes
42%

No
58%

Are you awarre about Neuro oncology?

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 33 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

MRI Scan are becoming very common but even then people get fear while performing those tests so they don’t prefer 

to take tests even though they have the related symptoms so that we got the answer mostly as ‘no’(69%) 

 

yes
30%

no
69%

maybe
1%

Have you gone through any test or MRI/scannings?

Yes
16%

no
84%

Did you consult a doctor ?

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 34 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Moving to Neurologist now is not usual because most of the people said ‘no’ (84%) . They move only if the general 

doctor gives an expert opinion. 

 

No relevant disease observed so ultimately they prefer no (90%) medications. Very rare case are prevalent so they 

might take medications (10%). 

 

yes
10%

no
90%

Are you taking medications?

26.20%

62.10%

11.70%

Do you think major death cases are due to cancers?

 Yes no maybe

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 35 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

In this survey we can see most of the people knew 

about neuro oncology and its common symptoms. 

Tumors, brain cancers is a common neurological 

disorder characterized by recurrent headaches. 

Typically, the associated  symptoms affects a person so 

much as it’s all basic signs a person can suffer from 

nausea, difficulty in walking, headaches, changes in 

personality etc. The pain is generally made worse by 

physical activity during an attack, although regular 

physical exercise may prevent future attacks. Up to 

one-third of people affected have aura: typically, it is a 

short period of visual disturbance that signals or 

harmful radiation will effect it. Occasionally, aura can 

occur with little or no following symptoms ,but not 

everyone has this symptoms. 

DISCUSSION 

When analyzing the efficiency of knowledge 

assimilation, the compared options, in contrast to the 

analysis of minimizing costs are characterized by 

greater or lesser, but not equivalent, efficiency. 

In this regard, it is important to assess the degree of 

feasibility of the analysis, depending on the level of 

reliability of the data. The test results were expressed 

in points Participants' results were calculated using 

Microsoft Excel software. The assessment of the 

effectiveness of the assimilation of knowledge was 

calculated based on the application of the proposed 

methodological recommendation in practice Thus, 

each participant of the survey, on average. Increased 

his theoretical and practical level of knowledge in the 

field of Neuro Oncology and it's prevention by almost 

half. 

CONCLUSION 

Its concluded from my survey also that many people 

nowadays are going through common symptoms but 

weren’t aware about it. Now after participating in my 

survey they would have got more awareness than 

before. If people are receiving any kind of symptom 

they should obviously consult the doctor as soon as 

possible. They shouldn’t take risk in it because the 

death rate in this case are literally very high and no 

proper medication can work if the condition goes out 

of hand .  

RECOMMENDATION 

➢ Avoid environmental hazards such as smoking and 

excessive radiation exposure 

➢ Manage stress 

➢ Relaxation techniques like meditation, yoga and 

mindful breathing can help 

➢ Eat on a regular schedule 

➢ Drink lots of fluids 

➢ Get plenty of rest 

➢ Get regular moderate exercise 

➢ Ask your doctor about preventive medicines if you 

get  

➢ Try getting lots of oxygen 

REFERENCES  

1. Haddad P, Shazadi S, Samiei F, Kharrazi HH, 

Tabatabaeefar M, Rakhsha A, Faranoosh M, 

Torabi-Nami M, Dadras A, Liaghi A, Nafarieh L. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 05-2023 36 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 05     Pages: 24-36 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

An overview of neuro-oncology research and 

practice in Iran, three years with the NOSC 

initiative. Int J Clin Exp Med. 2015 Mar 

15;8(3):3946-55. PMID: 26064296; PMCID: 

PMC4443130.  

2. Aizer AA, Lamba N, Ahluwalia MS, Aldape K, 

Boire A, Brastianos PK, Brown PD, Camidge DR, 

Chiang VL, Davies MA, Hu LS, Huang RY, 

Kaufmann T, Kumthekar P, Lam K, Lee EQ, Lin 

NU, Mehta M, Parsons M, Reardon DA, 

Sheehan J, Soffietti R, Tawbi H, Weller M, Wen 

PY. Brain metastases: A Society for Neuro-

Oncology (SNO) consensus review on current 

management and future directions. Neuro 

Oncol. 2022 Oct 3;24(10):1613-1646. doi: 

10.1093/neuonc/noac118. PMID: 35762249; 

PMCID: PMC9527527. 

3. Armstrong TS. Survivorship in Neuro-

Oncology. Neuro Oncol. 2018 Nov 

9;20(suppl_7):vii4-vii5. doi: 

10.1093/neuonc/noy173. PMID: 30412259; 

PMCID: PMC6225750. 

4. Мирхамидова С. М., Динмухаммадиев Н. А. 

Особенности распространенности 

онкологических заболеваний //Молодой 

ученый. – 2016. – №. 20. – С. 84-87. 

5. Levin VA. Drug discovery in neuro-oncology: 

challenges in the path forward. Neuro Oncol. 

2018 Mar 27;20(4):435-436. doi: 

10.1093/neuonc/noy004. PMID: 29538691; 

PMCID: PMC5909643.  

6. Millward CP, Armstrong TS, Barrington H, 

Brodbelt AR, Bulbeck H, Byrne A, Dirven L, 

Gamble C, Grundy PL, Islim AI, Javadpour M, 

Keshwara SM, Krishna ST, Mallucci CL, Marson 

AG, McDermott MW, Meling TR, Oliver K, Pizer 

B, Plaha P, Preusser M, Santarius T, 

Srikandarajah N, Taphoorn MJB, Watts C, 

Weller M, Williamson PR, Zadeh G, Zamanipoor 

Najafabadi AH, Jenkinson MD. Opportunities 

and challenges for the development of "core 

outcome sets" in neuro-oncology. Neuro 

Oncol. 2022 Jul 1;24(7):1048-1055. doi: 

10.1093/neuonc/noac062. PMID: 35287168; 

PMCID: PMC9248398. 

7. Lin E, Rosenthal MA, Le BH, Eastman P. Neuro-

oncology and palliative care: a challenging 

interface. Neuro Oncol. 2012 Sep;14 Suppl 4:iv3-

7. doi: 10.1093/neuonc/nos209. PMID: 

23095828; PMCID: PMC3480249. 

 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

